Template:Trichomonas antibiotics: Difference between revisions
| Line 1: | Line 1: | ||
====Non-Pregnant==== | ====Non-Pregnant==== | ||
*[[Metronidazole]] 2g PO once or 500mg PO BID for 7 days | *[[Metronidazole]] 2g PO once or 500mg PO BID for 7 days <ref>Kissinger P et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomised controlled trial. Lancet Infect Dis 2018 Oct 5; [e-pub].</ref> | ||
*[[Tinidazole]] 2g PO once | *[[Tinidazole]] 2g PO once | ||
====Pregnant==== | ====Pregnant==== | ||
''Only treat if the patient is symptomatic and avoid breast feeding until 24-hrs after last dose'' | ''Only treat if the patient is symptomatic and avoid breast feeding until 24-hrs after last dose'' | ||
Revision as of 23:50, 20 November 2018
Non-Pregnant
- Metronidazole 2g PO once or 500mg PO BID for 7 days [1]
- Tinidazole 2g PO once
Pregnant
Only treat if the patient is symptomatic and avoid breast feeding until 24-hrs after last dose
- Metronidazole 2g PO once[2]
Sexual Partner Treatment
- Metronidazole 500mg PO BID x 7 days or Tinidazole 2g PO once
Women with HIV Infection
- Metronidazole 500 mg PO BID x 7 days[3]
- ↑ Kissinger P et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: An open-label, randomised controlled trial. Lancet Infect Dis 2018 Oct 5; [e-pub].
- ↑ CDC Trichomoniasis 2015. https://www.cdc.gov/std/tg2015/trichomoniasis.htm
- ↑ CDC. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2010;59(No. RR-12)